Clinical Trial

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 8, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC).
Protocol Amendment History 36 amendments
This ClinicalTrials.gov record has been amended 36 times since 2019-10-21; most recent amendment 2025-08-06.
Status change: Recruiting → Active, Not Recruiting 2023-08-01
Status change: Not Yet Recruiting → Recruiting 2020-02-10
Trial Details
NCT Number NCT04136171
Lead Sponsor Ionis Pharmaceuticals, Inc.
Collaborators: AstraZeneca
Conditions Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Enrollment 1,438 participants
Start Date 2020-03-13
Primary Completion 2026-04 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-08-08